RE:Our Results are stronger and getting better !The most common AEs experienced in the nivolumab-combination therapy arm, occurring in 15% or more patients, were nausea, fatigue, musculoskeletal pain, constipation, decreased appetite, rash, vomiting, peripheral neuropathy, urinary tract infection, diarrhea, edema, hypothyroidism, and pruritus.